BostonGene, a leader in AI-driven molecular and immune profiling, will showcase its advanced technologies at the 14th World Clinical Biomarkers & CDx Summit 2024, held from September 3 – 6 in Boston. The summit gathers professionals to advance biomarker-driven clinical trials and precision therapies. BostonGene will be at booth #19 and will present a talk on enhancing immunotherapy trials.
Session Details:
- Title: Designing More Effective Trials with Integrated Immune Profiling of Peripheral Blood and Tumor Tissue
- Date & Time: Friday, September 6 | 2:35 PM
- Speaker: Michael Goldberg, PhD, VP of R&D, BostonGene
The talk will cover the integration of immune profiling in immunotherapy, focusing on identifying immunological signatures, evaluating patient immune status, and uncovering biomarkers for personalized treatment. It will address the use of transcriptional profiling and circulating cell-free RNA to predict drug responses and make real-time treatment decisions.
“Immunotherapy can revolutionize oncology, but its success hinges on accurately matching patients to therapies. Our AI platform provides detailed immune system profiling, helping clinicians make tailored treatment decisions and improve patient outcomes,” said Michael Goldberg, PhD, VP of R&D at BostonGene.
About BostonGene Corporation
Founded in 2015, BostonGene is committed to advancing cancer medicine through technology and personalized care. The company’s AI-powered multiomics platform offers comprehensive analysis of cancer patients’ molecular profiles, including the immune system and tumor microenvironment, to discover signatures, identify targets, and recommend effective treatments.
